Eugenics verification program suspended

Published 11:14am Friday, June 22, 2012

RALEIGH Without funding the process cannot continue.

Due to the joint budget agreement to exclude funding for compensation for victims of the states former Eugenics Board program, as well as continuation funding for operation of the N.C. Justice for Sterilization Victims Foundation, the Foundation has suspended intake of new victim verification requests.

The House approved legislation earlier this month that reflected Gov. Bev Perdues call to pay $50,000 lump sum compensation to living victims, as well as funding for the Foundations continued operation and expanded outreach. House Speaker Thom Tillis restated his personal support for House Bill 947, but added: There is a very strong message from the Senate that they are not prepared to take it up this year.

Foundation Executive Director Charmaine Fuller Cooper said the Foundation must curtail intake requests because its current operational funding is scheduled to expire on June 30, the end of the fiscal year. Other operational matters will be addressed soon.

The Foundation confirmed an increase in the number of verified victims, which counts 161 individuals in 57 counties, including 146 living victims. Fuller Cooper said the increase reflects cases of multiple siblings and entire families being sterilized. One of those victims resides in Hertford County, where 106 sterilization procedures (the 10th highest in the state) were performed during the peak years of the program (1946-1968).

Cooper noted that time is not on the side of aging victims. An updated estimate from the N.C. State Center for Health Statistics this month revised down the number of likely living victims from about 1,500 to 2,000 to about 1,350 to 1,800.

As of June 20, Lenoir County continues to have the highest number of verifications with 24 matches to N.C. Eugenics Board records. Mecklenburg, which had the highest number of procedures of any North Carolina county, follows with 13 verifications, then Wake with 11.

The N.C. Eugenics Board implemented a program of involuntary sterilization that took place in all 100 counties between 1929 and 1974. By the end of the program, nearly 7,600 documented people were sterilized.

See the original post here:

Eugenics verification program suspended

Eco-café celebrates successful first year

Buy This Photo

Photo by Beth Perdue/SCBB Center Cafe owner, Carol Fisher, gets ready for the cafe's one-year birthday celebration. Designed with eco-friendly principles, the cafe has become a neighborhood favorite in New Bedford's South End.

By Beth Perdue

June 22, 2012 1:56 PM

NEW BEDFORD A sustainably-focused eco-caf in the city's South End celebrated its first full year in business in mid-June, holding a neighborhood party on a tree-top patio above the caf.

Owned and designed by Carol Fisher, the Center Caf is a small coffeehouse offering coffee, ice cream, breakfast and lunch items in a mixed residential and small business neighborhood close to New Bedford's beaches.

Fisher is also the owner of Effortless Design, a Charlestown-based design/build business that offers architectural, engineering, and construction management services. She tapped her design skills and interest in creating sustainable businesses when designing the New Bedford caf.

"A lot of (our sustainability work) comes from having a neighborhood focus, of having a place in the neighborhood, that people can walk to as an alternative to fast food," said Fisher.

Many customers typically come from within a four-to-five-block radius of the caf, Fisher said, allowing them to walk there. Being in a city neighborhood helps her business flourish while the cafe's presence also benefits the neighborhood, by adding a desirable amenity.

"People are glad that there's a little neighborhood caf when they move in or when they're looking at buying," said Fisher. "It really says something about the neighborhood."

Originally posted here:

Eco-café celebrates successful first year

Wrack washes ashore on Tybee Island, HHI beaches

TYBEE ISLAND, GA (WTOC) -

A supermoon and a tropical storm has caused a lot of natural debris to wash up on some area beaches.

On Tybee Island, dried marks grasses, known as wrack, and sargrassum seaweed is washing ashore. Officials say that debris is good for the beaches by is making some tourists unhappy.

Tybee officials spent Friday scrapping beaches on the northern end of the island after the Department of Natural Resources told Tybee that they could resume scrapping. They ordered them to stop earlier because of complaints.

Wrack is also washing up on the lowcountry beaches. State officials say it helps stop erosion, especially this time of the year with all of the storms.

Seaweed and wrack can be removed as long as it is below the high tide line.

Copyright 2012WTOC. All rights reserved.

More:

Wrack washes ashore on Tybee Island, HHI beaches

Near-Earth asteroid twice as big as previously thought | Bad Astronomy

On June 14, 2012, the asteroid 2012 LZ1 passed the Earth. It missed us by a wide margin, over 5 million kilometers (3 million miles), so there was no danger of impact. While it does get near us every now and again, using current orbital measurements we know were safe from an impact by this particular rock for at least 750 years. Phew.

Good thing, too. New observations using the Arecibo radio telescope in Puerto Rico indicate LZ1 is bigger than we first thought. Much bigger: its about a kilometer across, when it was thought to be half that size before these observations.

Thats a big difference. The problem is that the size of an asteroid is hard to determine. Even a big one may only appear as a dot in a telescope, so even though we may know its distance and trajectory very accurately, directly measuring its size isnt possible. Usually, the size is estimated by knowing its distance and how bright it appears. In general, a bigger rock will look brighter than a smaller one at a given distance.

But that assumes they both reflect the same amount of light. Most asteroids reflect about 4% of the sunlight they receive (this property is called the albedo), but that depends on their surface. Some have darker surfaces, some brighter. If you dont know how reflective it is, the size can only be estimated.

But the Arecibo telescope can actually directly measure the size of a nearby asteroid. It can send pulses of radio waves at an asteroid and then receive the reflected waves, much like a cop on the side of the road uses radar to measure a cars speed. The method is technical (Emily Lakdawalla has a great explanation on her blog), but it was used for LZ1 to get the new size measurement. The picture above is the actual image generated using Arecibo when the rock was still 10 million km (6 million miles) from Earth. Apparently, LZ1 is much less reflective than assumed earlier, which is why the size was underestimated by a factor of two.

An asteroid this size hitting the Earth would be, um, bad. Thats big enough to be considered a global hazard, causing immense devastation. It might not be an extinction event the dinosaur-killing asteroid was 10 km across, so it had 1000 times the mass of LZ1 but it wouldnt be fun. So Im glad were safe from this guy for some time!

But Ill be honest: LZ1 was only discovered a few weeks before it passed us. Asteroids this size passing near us are pretty rare (we havent had an impact from something this big for many, many millennia) so as usual Im not panicking about this. But it just shows once again that we need more eyes on the sky, more people looking. And we need a plan in place in case we do see one with our name on it.

Related Posts:

- Asteroid 2011 AG5: a football-stadium-sized rock to watch carefully - My asteroid impact talk is now on TED - Another tiny rock will pass Earth tomorrow - Updated movie of asteroid YU55, plus bonus SCIENCE - Just to be clear: asteroid YU55 is no danger to Earth - Armageddon delayed by at least a century this time

Continue reading here:

Near-Earth asteroid twice as big as previously thought | Bad Astronomy

2012 Music and Astronomy Under the Stars Events

Join Dr. Donald Lubowich, coordinator of the Astronomy Outreach Program at Hofstra University, for a series of events bringing astronomy to the public. Concertgoers at several events this summer will get a glimpse of heavens along with their music.

This NASA-sponsored program will include optical and radio telescope observations of the Sun prior to the concerts. Observations of the moon, planets, multi-colored double stars, star clusters and nebulae will be featured at intermission and after the concerts. Videos, posters, hands-on activities and the sounds of the sun will also be available.

For more information and to see a full schedule of events, visit http://www.hofstra.edu/Academics/Colleges/HCLAS/PHYSIC/physic_underthestars.html.

Please follow SpaceRef on Twitter and Like us on Facebook.

Original post:

2012 Music and Astronomy Under the Stars Events

No words | Bad Astronomy

Phil Plait, the creator of Bad Astronomy, is an astronomer, lecturer, and author. After ten years working on Hubble Space Telescope and six more working on astronomy education, he struck out on his own as a writer. He's written two books, dozens of magazine articles, and 12 bazillion blog articles. He is a skeptic and fights the abuse of science, but his true love is praising the wonders of real science.

The original BA site (with the Moon Hoax debunking, movie reviews, and all that) can be found here.

Read the original here:

No words | Bad Astronomy

The swirling maelstrom of the sun, pictured in outstanding detail during the Transit of Venus by one dedicated space …

By Eddie Wrenn

PUBLISHED: 12:28 EST, 22 June 2012 | UPDATED: 13:27 EST, 22 June 2012

It is difficult to think of the sun as anything more than how we view it from Earth - a great, bright ball, uniform in appearance as it placidly heats our planet.

But seen in close-up, the view is startling - a raging sea of fire, as the hydrogen fuel of the sun burns away in a five-billion-year explosion.

The artistic, and out-of-this-world photographs were taken by sun enthusiast and solar photographer Alan Freidman, from the Mount Wilson Observatory near Los Angeles, California.

The sun the day before: Alan set up his solar equipment at Mount Wilson the day before the Transit of Venus and ran a test to make sure that everything had survived the trip and was working well

The detail captured by Alan is stunning: Far from being the placid, uniform ball we see each day, the sun is a raging and turbulent ball of flames

Alan, described as a 'master of solar photography' by Discovery News, took this first image a day before the transit of Venus earlier this month.

He was preparing his equipment in advance of the transit, and his practice runs led to these stunning images.

What we see here are the mingling of the upper layers of the sun - known as the photosphere and chromosphere.

Read more here:

The swirling maelstrom of the sun, pictured in outstanding detail during the Transit of Venus by one dedicated space ...

Alan Turing – Life and Tragic Death of Enigma and Computing Hero

Saturday, 23 June will mark 100 years since the birth of Alan Turing, who not only spearheaded Britain's code breaking at Bletchley Park which saw the German Enigma machine cracked, but also researched artificial intelligence and helped to create the world's first commercially sold computer.

Born in Maida Vale, London in 1912, Turing showed signs from a young age that he was a particularly gifted child when it came to mathematics and went on to study the subject at King's College, Cambridge, where he gained a first-class honours degree at the age of 21.

Bletchley Park and Cracking the Enigma

During the Second World War, Turing joined the war effort at Bletchley Park, Buckinghamshire, where he worked with a team of mathematicians to try and crack the German Enigma code using an electromagnet machine called a "bombe".

Like us on Facebook

The bombe searched for possible correct settings used for an Enigma message and for each possible setting the bombe performed a chain of logical deductions.

Detecting when a contradiction had occurred, the bombe ruled out that setting and moved on to the next.

Most of the possible settings would cause contradictions and be discarded, leaving only a few to be investigated in detail. The first bombe was installed on 18 March 1940, but by the end of the war more than 200 bombes were in use.

Artificial Intelligence and the Turing Test

Read more:

Alan Turing - Life and Tragic Death of Enigma and Computing Hero

'A Perfect and Beautiful Machine': What Darwin's Theory of Evolution Reveals About Artificial Intelligence

Charles Darwin and Alan Turing, in their different ways, both homed in on the same idea: the existence of competence without comprehension.

@FakeTV

Some of the greatest, most revolutionary advances in science have been given their initial expression in attractively modest terms, with no fanfare.

Charles Darwin managed to compress his entire theory into a single summary paragraph that a layperson can readily follow.

Francis Crick and James Watson closed their epoch-making paper on the structure of DNA with a single deliciously diffident sentence. ("It has not escaped our notice that the specific pairings we have postulated immediately suggests a possible copying mechanism for the replicating unit of life.")

And Alan Turing created a new world of science and technology, setting the stage for solving one of the most baffling puzzles remaining to science, the mind-body problem, with an even shorter declarative sentence in the middle of his 1936 paper on computable numbers:

It is possible to invent a single machine which can be used to compute any computable sequence.

Turing didn't just intuit that this remarkable feat was possible; he showed exactly how to make such a machine. With that demonstration the computer age was born. It is important to remember that there were entities called computers before Turing came up with his idea, but they were people, clerical workers with enough mathematical skill, patience, and pride in their work to generate reliable results of hours and hours of computation, day in and day out. Many of them were women.

Early "computers" at work. (NASA)

Thousands of them were employed in engineering and commerce, and in the armed forces and elsewhere, calculating tables for use in navigation, gunnery and other such technical endeavors. A good way of understanding Turing's revolutionary idea about computation is to put it in juxtaposition with Darwin's about evolution. The pre-darwinian world was held together not by science but by tradition: All things in the universe, from the most exalted ("man") to the most humble (the ant, the pebble, the raindrop) were creations of a still more exalted thing, God, an omnipotent and omniscient intelligent creator -- who bore a striking resemblance to the second-most exalted thing. Call this the trickle-down theory of creation. Darwin replaced it with the bubble-up theory of creation. One of Darwin's nineteenth-century critics, Robert Beverly MacKenzie, put it vividly:

Continued here:

'A Perfect and Beautiful Machine': What Darwin's Theory of Evolution Reveals About Artificial Intelligence

Acobot Offers Free Live Chat Robot to Nonprofits, Education and Government

SUNNYVALE, Calif., June 22, 2012 /PRNewswire/ -- Acobot, the chatbot using artificial intelligence (AI) technology to assist website visitors 24 hours a day, is now free to nonprofit organizations, education providers, and government entities.

"Nonprofit, education and government organizations need to improve their online results every bit as much as for-profit business enterprises do," explained Acobot LLC founder and CEO Vic Duan. "However, they rarely have the financial and technological resources to apply new web technologies. Acobot can help these worthy organizations achieve their goals and better serve their website visitors."

The Acobot AI chat technology allows websites to interact with visitors automatically. Site owners can set up Acobot in minutes; once the system is up and running, the robot learns more with each visit, making it better able to "talk" to users and answer their questions with repeated use.

Organizations interested in using AI chat technology to assist their website visitors can obtain their own live Acobot robot at Acobot.com by signing up and indicating that their sites are for non-commercial use. Once signed up, an organization immediately receives a fully functional robot hosted by Acobot.com. There is no limit to the Acobot chat sessions, and the robot is permanently free.

While it aims to help nonprofits, education providers and governments optimize their site visitors' online experience without straining strapped budgets, Acobot admits that the arrangement is mutually beneficial. "The more people use the robot, the more linguistic data we'll obtain," Duan said. "The company uses that data to improve the AI live chat software continuously."

Non-commercial websites can learn more about Acobot AI chat technology, try out the robot, and sign up for free at http://acobot.com.

About Acobot LLC

Acobot develops state-of-the-art artificial intelligence technology and helps small to medium-sized businesses and nonprofit organizations improve their online results with AI chat applications.

Contact:

Vic Duan Acobot LLC Tel: (408) 351-6618 info@acosys.com

See the article here:

Acobot Offers Free Live Chat Robot to Nonprofits, Education and Government

Big Tech: China’s Biggest Challenge Is Aerospace

Photo illustration: Bartholomew Cooke

From the outside, the only question about Chinas nonstop growth is which milestone the country will roar past next. China is already the second-largest economy in the world, after not making the top 10 just a generation ago. According to some growth-rate predictions, its now within a generation of overtaking the US and becoming number one. And by many measures, its already in first place: New roads built, cars bought, mobile phones in service, Internet users signed onbased on these and other categories, the center of the worlds economic activity has moved to China.

From inside China, things look dicier. The country has plenty of problems: an environmental catastrophe that has made cancer the leading cause of death, tensions that arise in one of the most unequal societies on earth, challenges to the legitimacy of the only major government that does not let its people vote. And while Americans and other outsiders fear that China has devised the economic model of the future, many of the countrys leaders worry that the model has run its course. Even in China there are only so many dams to be built, high-speed railroad lines to be laid, brand-new cities to be populated. China has proven that you can move people en masse from rural poverty to urban factory life in a single generation, by embracing the role of outsourcing workhouse of the world. But Chinese economists fear that this may turn into a low-wage trap that will keep the country from creating the kind of large professional, high-end entrepreneurial, and upper-middle classes that the US has long enjoyed.

Thus the Chinese determination, spelled out in its 12th Five-Year Plan to move up the value chain. Can it succeed? Will the next Apples, Facebooks, and Googles arise in China? How much do the current Pfizers, GEs, and Boeings have to fear?

The answer will be found in apex industries, those clusters of businesses whose vitality signals the presence of surrounding networks of high-value skills, technologies, and operational competencies. Wildlife biologists look for healthy populations of amphibiansnewts, frogsto indicate the broader health of a wetland environment. Similarly, economic analysts can look to the status of pharmaceutical industries (which reflect a strong research culture), university complexes (whose ability to draw and hold the worlds talent reflects the attractiveness of a society), and venture capital and info-tech industries (which depend on openness) to judge overall economic vitality. And in China they should be looking at aerospace.

Aerospace has long been an American bulwark. In most years Boeing is the nations leading exporter. America has more airports, builds more airplanes, trains more pilots, and arranges more of its economy around aviation than any other country, by far. China would very much like a piece of thisto have Boeings, NASAs, Cessnas, and fully fledged GPS systems of its own. The 12th Five-Year Plan lists aerospace as a symbol and target of Chinas high-value ambition. Over the next few years, the country will attempt to re-create all of Americas 100-year aerospace history: from the glamor and popularization of flying in the Lindbergh era of the 1920s, through the airport-building boom of the 1940s and 1950s and the moon race in the 1960s, to the routinization (and immiseration) of airline flight now.

OK, the Chinese hope to skip the immiseration. Otherwise theyre trying to do it all, with 100 airports under construction, several airliner models being developed, and a business-jet culture taking hold.

The most ambitious of these efforts, a moon shot, reveals the least about the countrys high-value potential. In a sense, its a flying version of the Three Gorges Dam, one more massive public-works effort. The more significant apex-industry test is whether the Chinese system can integrate the complex array of tasks necessary to build safe airplanes and manage safe airlines, at much higher volumes and on tighter schedules than they currently do (like those in the US and Europe). Targets include shared public and private responsibility for safety, shared military and civilian control of airspace, international standards applied in a domestic setting, and the balance between strict by-the-book procedure and individual initiative that keep aerial challenges like the Miracle on the Hudson landing from turning into tragedies.

This industry is the perfect test case of economic maturity, a longtime Boeing and FAA employee named Joe Tymczyszyn told me in Beijing, where he has moved to help the Chinese develop their aerospace industry. So to truly understand how close China is to realizing its potential, keep your eye on the skies.

James Fallows (jamesfallows@theatlantic.com) is the author of the new book China Airborne.

Read more:

Big Tech: China’s Biggest Challenge Is Aerospace

Brain Stimulation for Parkinson’s Offers Improvements in Symptoms Over Three Years

WASHINGTON--(BUSINESS WIRE)--

Patients with Parkinsons disease who undergo deep brain stimulation (DBS)a treatment in which a pacemaker-like device sends pulses to electrodes implanted in the braincan expect stable improvement in muscle symptoms for at least three years, according to a Department of Veterans Affairs study appearing in the most recent issue of the journal Neurology.

VA was proud to partner with the National Institutes of Health in this research, said Secretary of Veterans Affairs Eric K. Shinseki. Our research on Parkinsons helps ensure we continue to provide the best care possible for Veterans with this debilitating disease.

VA cares for some 40,000 Veterans with the condition.

In DBS, surgeons implant electrodes in the brain and run thin wires under the skin to a pacemaker-like device placed at one of two locations in the brain. Electrical pulses from the battery-operated device jam the brain signals that cause muscle-related symptoms. Thousands of Americans have seen successful results from the procedure since it was first introduced in the late 1990s. But questions have remained about which stimulation site in the brain yields better outcomes, and over how many years the gains persist.

Initial results from the study appeared in 2009 in the Journal of the American Medical Association. Based on the six-month outcomes of 255 patients, the researchers concluded that DBS is riskier than carefully managed drug therapybecause of the possibility of surgery complicationsbut may hold significant benefits for those with Parkinsons who no longer respond well to medication alone.

A follow-up report in the New England Journal of Medicine in 2010, using data from 24 months of follow-up, showed that similar results could be obtained from either of the two brain sites targeted in DBS.

The new report is based on 36 months of follow-up on 159 patients from the original group. It extends the previous findings: DBS produced marked improvements in motor (movement-related) function. The gains lasted over three years and did not differ by brain site.

Patients, on average, gained four to five hours a day free of troubling motor symptoms such as shaking, slowed movement, or stiffness. The effects were greatest at six months and leveled off slightly by three years.

According to VA Chief Research and Development Officer Joel Kupersmith, MD, This rigorously conducted clinical trial offers valuable guidance for doctors and patients in VA and throughout the world. As our Veteran population and the general U.S. population grow older, this research and future studies on Parkinsons will play an important role in helping us optimize care.

Visit link:
Brain Stimulation for Parkinson’s Offers Improvements in Symptoms Over Three Years

uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease

AMSTERDAM, June 21, 2012 /PRNewswire/ --

uniQure, a leader in the field of human gene therapy, announced today the signing of a collaborative agreement with two leading neurology experts to develop further a gene therapy incorporating uniQure's GDNF (glial cell derived neurotrophic factor) gene for the treatment of Parkinson's disease.

Professor Krystof Bankiewicz at the University of California, San Francisco (UCSF), a world expert in GDNF gene therapy, and Professor Howard Federoff of Georgetown University, a preeminent physician-neuroscientist, have developed a product approved to start clinical trials in the U.S. using uniQure's GDNF gene incorporated into an adeno-associated virus-2 (AAV-2) delivery vector. The GDNF gene contains the information to produce a protein necessary for the development and survival of nerve cells. The positive effect of GDNF on nerve cells has already been demonstrated in early research by uniQure in collaboration with the University of Lund, Sweden.

UCSF entered into a collaboration with Dr. Russell Lonser, neurosurgeon and Chief of the Neurosurgical Branch of the NINDS, a division of the National Institutes of Health, to commence a Phase I study of the gene therapy in patients with Parkinson's disease. Patient enrollment is expected to begin mid-2012. Collaborating on the study will be Drs. Krystof Bankiewicz of UCSF, Howard Federoff of Georgetown University and NINDS co-investigator neurologists Drs. Mark Hallett and Walter Koroshetz.

"This agreement provides uniQure with access to the data from a Parkinson's disease GDNF clinical study conducted by two of the world's leading medical researchers in the field. If successful, we intend to manufacture the vector construct ourselves and with a partner progress the product into advanced clinical studies," said Jrn Aldag, CEO of uniQure. "GDNF has been shown to be involved in several other CNS disorders so if we reach the proof of concept stage in Parkinson's, we can potentially expand product development quickly and efficiently into clinical trials for other indications, such as Huntington's and Multiple System Atrophy (MSA)."

"The development of AAV2-GDNF, sponsored by both NIH and by Parkinson's foundations, has taken us 10 years to complete. We are very pleased that a path for clinical development of AAV2-GDNF as a possible treatment for PD is now in place," said Dr. Krystof Bankiewicz, UCSF Principal Investigator.

Under the terms of uniQure's agreement with UCSF, uniQure holds the exclusive commercial rights to all UCSF preclinical data and to IND enabling Phase I clinical data provided to UCSF by NINDS. In the event that the Phase 1 study shows proof of concept, uniQure will use its proprietary manufacturing system for future production of the AAV construct and take responsibility for future development of the gene therapy product. uniQure holds the exclusive license to the GDNF gene from Amgen.

About uniQure

uniQure is a world leader in the development of human gene based therapies. uniQure has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows uniQure to pursue its strategy of focusing on this sector of the industry. Further information can be found at http://www.uniqure.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of uniQure only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of uniQure. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting uniQure's business. uniQure expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.

Read more:
uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease

uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson’s Disease

AMSTERDAM, June 21, 2012 /PRNewswire/ --

uniQure, a leader in the field of human gene therapy, announced today the signing of a collaborative agreement with two leading neurology experts to develop further a gene therapy incorporating uniQure's GDNF (glial cell derived neurotrophic factor) gene for the treatment of Parkinson's disease.

Professor Krystof Bankiewicz at the University of California, San Francisco (UCSF), a world expert in GDNF gene therapy, and Professor Howard Federoff of Georgetown University, a preeminent physician-neuroscientist, have developed a product approved to start clinical trials in the U.S. using uniQure's GDNF gene incorporated into an adeno-associated virus-2 (AAV-2) delivery vector. The GDNF gene contains the information to produce a protein necessary for the development and survival of nerve cells. The positive effect of GDNF on nerve cells has already been demonstrated in early research by uniQure in collaboration with the University of Lund, Sweden.

UCSF entered into a collaboration with Dr. Russell Lonser, neurosurgeon and Chief of the Neurosurgical Branch of the NINDS, a division of the National Institutes of Health, to commence a Phase I study of the gene therapy in patients with Parkinson's disease. Patient enrollment is expected to begin mid-2012. Collaborating on the study will be Drs. Krystof Bankiewicz of UCSF, Howard Federoff of Georgetown University and NINDS co-investigator neurologists Drs. Mark Hallett and Walter Koroshetz.

"This agreement provides uniQure with access to the data from a Parkinson's disease GDNF clinical study conducted by two of the world's leading medical researchers in the field. If successful, we intend to manufacture the vector construct ourselves and with a partner progress the product into advanced clinical studies," said Jrn Aldag, CEO of uniQure. "GDNF has been shown to be involved in several other CNS disorders so if we reach the proof of concept stage in Parkinson's, we can potentially expand product development quickly and efficiently into clinical trials for other indications, such as Huntington's and Multiple System Atrophy (MSA)."

"The development of AAV2-GDNF, sponsored by both NIH and by Parkinson's foundations, has taken us 10 years to complete. We are very pleased that a path for clinical development of AAV2-GDNF as a possible treatment for PD is now in place," said Dr. Krystof Bankiewicz, UCSF Principal Investigator.

Under the terms of uniQure's agreement with UCSF, uniQure holds the exclusive commercial rights to all UCSF preclinical data and to IND enabling Phase I clinical data provided to UCSF by NINDS. In the event that the Phase 1 study shows proof of concept, uniQure will use its proprietary manufacturing system for future production of the AAV construct and take responsibility for future development of the gene therapy product. uniQure holds the exclusive license to the GDNF gene from Amgen.

About uniQure

uniQure is a world leader in the development of human gene based therapies. uniQure has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows uniQure to pursue its strategy of focusing on this sector of the industry. Further information can be found at http://www.uniqure.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of uniQure only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of uniQure. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting uniQure's business. uniQure expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.

Read more:
uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease

Device Calms Parkinson's Tremor for 3+ Years

Quality of Life, Daily Living Did Not Improve in Study

By Denise Mann WebMD Health News

Reviewed by Laura J. Martin, MD

June 20, 2012 -- For some people with Parkinson's disease, deep brain stimulation can have immediate and dramatic effects on tremors, rigidity, balance, and other motor symptoms.

Now new research shows that these benefits may last at least three years. The findings appear online in Neurology.

Deep brain stimulation uses a battery-operated device to deliver electrical impulses -- similar to a pacemaker for the heart -- to areas of the brain that control movement. The impulses are thought to block abnormal signals that cause many of the movement problems (motor symptoms) of Parkinson's. This procedure is typically reserved for individuals who no longer respond to their Parkinson's medications or who experience unacceptable side effects from them.

According to the new findings, this treatment helped with motor symptoms such as tremor, but individuals did show gradual declines over time in their quality of life, ability to perform tasks of daily living, and thinking skills.

"This study looked past the immediate 'wow effect,'" says Michele Tagliati, MD. He wrote an editorial accompanying the new study.

"Now we want to know what we can expect over the next 10 years, and this starts to make it clearer," says Tagliati, the director of the Movement Disorders Program at Cedars-Sinai Medical Center in Los Angeles.

"The effect on motor function is sustained," says researcher Frances M. Weaver, PhD. She is the director of the Center for Management of Complex Chronic Care at Edward Hines Jr. VA Hospital in Hines, Ill. But "deep brain stimulation does not have an impact on the other symptoms of the disease, so there will be progression."

Follow this link:
Device Calms Parkinson's Tremor for 3+ Years

Device Calms Parkinson’s Tremor for 3+ Years

Quality of Life, Daily Living Did Not Improve in Study

By Denise Mann WebMD Health News

Reviewed by Laura J. Martin, MD

June 20, 2012 -- For some people with Parkinson's disease, deep brain stimulation can have immediate and dramatic effects on tremors, rigidity, balance, and other motor symptoms.

Now new research shows that these benefits may last at least three years. The findings appear online in Neurology.

Deep brain stimulation uses a battery-operated device to deliver electrical impulses -- similar to a pacemaker for the heart -- to areas of the brain that control movement. The impulses are thought to block abnormal signals that cause many of the movement problems (motor symptoms) of Parkinson's. This procedure is typically reserved for individuals who no longer respond to their Parkinson's medications or who experience unacceptable side effects from them.

According to the new findings, this treatment helped with motor symptoms such as tremor, but individuals did show gradual declines over time in their quality of life, ability to perform tasks of daily living, and thinking skills.

"This study looked past the immediate 'wow effect,'" says Michele Tagliati, MD. He wrote an editorial accompanying the new study.

"Now we want to know what we can expect over the next 10 years, and this starts to make it clearer," says Tagliati, the director of the Movement Disorders Program at Cedars-Sinai Medical Center in Los Angeles.

"The effect on motor function is sustained," says researcher Frances M. Weaver, PhD. She is the director of the Center for Management of Complex Chronic Care at Edward Hines Jr. VA Hospital in Hines, Ill. But "deep brain stimulation does not have an impact on the other symptoms of the disease, so there will be progression."

Follow this link:
Device Calms Parkinson's Tremor for 3+ Years

Treating Orthostatic Hypotension Improves Function In Parkinson’s Disease Patients, According To Braintree …

BOSTON, June 21, 2012 /PRNewswire/ --A new study analyzing patient data from Braintree Rehabilitation Hospital in Braintree, Massachusetts, found that blood pressure fluctuations can worsen symptoms of Parkinson's disease. Conversely, after treating Parkinson's disease patients who experienced blood pressure drops when changing from a sitting to standing position, improvements were noted in cognitive function, balance and walking, according to the researchers at Braintree Rehabilitation Hospital.

Information from the study will be presented today at the Movement Disorder Society's 16th International Congress of Parkinson's Disease and Movement Disorders in Dublin, Ireland. The corresponding abstract, "Treating Orthostatic Hypotension in Patients with Parkinson's and Atypical Parkinsonism Improves Function," will be published as an electronic supplement to The Movement Disorders Journal online edition at http://www.movementdisorders.org.

"This new research sheds light for better Parkinson's disease treatment, as blood pressure can be affected by the disease and problems often worsen over time," said Dr. Anna DePold Hohler, Medical Director of the Movement Disorders Program at Braintree Rehabilitation Hospital and Associate Professor of Neurology at Boston University Medical Center, who participated in the study. "The good news for Parkinson's disease patients is that implementing simple interventions, monitored by a physician, can significantly improve functionality."

In the United States, 1.5 million people suffer from this complex neurodegenerative disorder. For this population, blood pressure drops may occur due to a decrease in the neurotransmitter norepinepherine and as a result of medications used to treat motor symptoms.

Depending on the patient, treatment strategies might include increasing water or salt intake, use of compression stockings, and slow position changes. Specific medications may also be warranted in patients at risk for fainting.

These findings update previous work conducted at Braintree Rehabilitation Hospital recently published in the International Journal of Neuroscience, 2011.

The Movement Disorders Program at Braintree Rehabilitation Hospital, a world-class rehabilitative care provider, allows patients to have physical, occupational and speech therapy along with medication adjustments, blood pressure adjustments, and deep brain stimulation adjustments as needed. As a result, improvements in patients are significant and a large number of individuals can be optimized to return home.

Braintree Rehabilitation Hospital is located at 250 Pond Street in Braintree, Massachusetts. For more information visit http://www.braintreerehabhospital.com, or call (781) 348-2500.

Media contact: CM Communications Lori Moretti or Meg Fitzgerald mfitzgerald@cmcommunications.com 617-536-3400

See original here:
Treating Orthostatic Hypotension Improves Function In Parkinson's Disease Patients, According To Braintree ...